Advocacy intelligence hub — real-time data for patient organizations
LUXTURNA: FDA approved
an adeno-associated virus vector-based gene therapy indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. Patients must have viable retinal cells determined by a treating physician
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations news →
View all Inherited cancer-predisposing syndrome due to biallelic BRCA2 mutations specialists →